Drug intelligence / Profile preview

LS-003

Development stage: Preclinical
Lead developer: Immorta Bio
Modality: Adoptive Cell Transfer → Cell Therapies, Stem Cell Therapies → Cell Therapies

Overview

**LS-003** is an Immorta Bio preclinical, personalized combination program for systemic longevity and disorders of aging. It combines **SenoVax**, an autologous senolytic immunotherapy intended to promote removal of senescent cells and reduce their harmful senescence-associated secretory phenotype activity, with **StemCell Revivify**, a personalized stem-cell therapy intended to restore more youthful stem-cell function. The program is designed as a complementary senescent-cell clearance and regenerative cell-therapy approach.

Other names: SenoVax + StemCell Revivify combination

Beyond the preview

Go deeper on LS-003.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on LS-003.

Explore the full profile